New Jersey Institute of Technology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, New Jersey Institute of Technology sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
New Jersey Institute of Technology: 5 sponsored US clinical trials, 1 recruiting.
New Jersey Institute of Technology sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Convergence Insufficiency, with 2 trials.
Upper-quartile sponsor footprint
New Jersey Institute of Technology sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Eye Recovery Automation for Post Injury Dysfunction (iRAPID)
NCT06105892
Persistent Post-Concussion Symptoms With Convergence Insufficiency
NCT05262361
Robot Assisted Virtual Rehabilitation for the Hand Post Stroke (RAVR)
NCT03569059
Neural Mechanism of Vision Therapy for Patients With Convergence Insufficiency
NCT03593031
Optimizing Hand Rehabilitation Post-Stroke Using Interactive Virtual Environments
NCT01072461
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the New Jersey Institute of Technology pipeline
1 recruiting of 5 indexed (20% open); 4 completed (80%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Convergence Insufficiency (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
New Jersey Institute of Technology: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
New Jersey Institute of Technology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this New Jersey Institute of Technology page
5 registered trials is a research-attention snapshot, not an endorsement of New Jersey Institute of Technology or any single study.
- 1 of New Jersey Institute of Technology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Convergence Insufficiency is the condition New Jersey Institute of Technology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Convergence Insufficiency trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
New Jersey Institute of Technology pipeline card: 5 registered trials from official public datasets.Report a data error.